News

Brain wave changes in sleep can predict levodopa-induced dyskinesia

People with Parkinson’s disease whose electrical brain wave activity declines more slowly during deep sleep develop levodopa-induced dyskinesia (LID), or uncontrolled movements, faster, a study has found. These findings confirm a link between sleep-related brain wave activity and LID, and support the development of sleep-targeted therapies that may protect…

NfL levels may mediate link between dementia, LRRK2 variants

Scientists have discovered that long-term changes in a biomarker of nerve damage, called neurofilament light chain (NfL), could be used to predict cognitive decline in people with Parkinson’s disease due to certain mutations. They found that a slower progression of dementia in people with LRRK2-associated Parkinson’s compared with those…

Single cell therapy may help to ease disease severity in Parkinson’s

Homogenous cell therapy — treatments using only one cell type — may ease disease severity, lessen motor symptoms, and improve activities of daily living in people with Parkinson’s disease, according to a new systematic review. These effects were observed during patients’ off periods, times when the medication wears off…

More evidence needed to support link between ADHD, Parkinson’s

While it appears that people with attention deficit hyperactivity disorder (ADHD) are more likely to develop Parkinson’s disease later in life than are individuals without the neurodevelopmental disorder, further proof is needed to establish a link, according to a new systematic review. “Our review provides preliminary results that a…

Asha Therapeutics selected to join Blue Knight for public health

Asha Therapeutics has been selected as a Blue Knight company, joining a public-private initiative that focuses on speeding new technology and science to help quickly and effectively deal with emerging dangers to public health and safety. The biopharmaceutical company’s selection was prompted by its proprietary therapeutic design platform, known…

Brain Canada program supports pair starting in Parkinson’s research

Future Leaders in Canadian Brain Research, a Brain Canada program, has awarded two early-career scientists CA$100,000 (about $74,180) each in grants to advance research projects into Parkinson’s disease. Maria Ioannou, PhD, an assistant professor of physiology at the University of Alberta, is exploring alpha-synuclein protein clumping, a hallmark…